Experimental combo shows promise for tough bile duct cancer

NCT ID NCT04203160

Terminated Disease control Sponsor: University of Michigan Rogel Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether adding an experimental drug called CPI-613 (devimistat) to standard chemotherapy (gemcitabine plus cisplatin) could help people with advanced biliary tract cancer that cannot be removed by surgery. The trial had two parts: first, finding the safest dose of CPI-613, then comparing the combination to chemotherapy alone. About 75 participants were planned, but the study was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CPI-613 (devimistat) plus gemcitabine and cisplatin
What this could lead to: If successful, this combination could improve response rates and delay cancer progression for people with advanced biliary tract cancer.
What could go wrong: The trial was terminated early, so results are limited. It is a small, early-phase study, and the added drug may increase side effects without clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer Biliary Tract Neoplasms cholangiocarcinoma gallbladder neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BILIARY TRACT CANCER

Contacts and locations

Locations

Allegheny Health Network

Pittsburgh, Pennsylvania, 15224, United States
Atlantic Health System

Morristown, New Jersey, 07960, United States
Fred Hutch/University of Washington Cancer Consortium

Seattle, Washington, 98109, United States
Northwestern University -- Lurie Comprehensive Cancer Center

Chicago, Illinois, 60611, United States
University Hospitals - Seidman Cancer Center

Cleveland, Ohio, 44106, United States
University of Arizona Cancer Center

Tucson, Arizona, 85724, United States
University of Michigan Rogel Cancer Center

Ann Arbor, Michigan, 48109, United States
University of Texas Southwestern -- Simmons Comprehensive Cancer Center

Dallas, Texas, 75390, United States
University of Wisconsin - Carbone Cancer Center

Madison, Wisconsin, 53705, United States
Vanderbilt-Ingram Cancer Center

Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.